Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
IVAX Research LLC National Cancer Institute (NCI) |
---|---|
Information provided by: | IVAX Research LLC |
ClinicalTrials.gov Identifier: | NCT00062504 |
To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.
Condition | Intervention | Phase |
---|---|---|
Glioblastoma Multiforme Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Mixed Oligoastrocytoma |
Drug: Talampanel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Parallel Assignment |
Official Title: | A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas. |
Enrollment: | 30 |
Study Start Date: | July 2003 |
Study Completion Date: | April 2006 |
Primary Completion Date: | January 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
|
Drug: Talampanel
10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
|
2: Experimental
Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
|
Drug: Talampanel
10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
|
3: Experimental
Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
|
Drug: Talampanel
10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
|
To determine the efficacy of Talampanel in patients with recurrent malignant glioma as measured by 6-month progression survival, as well as to obtain preliminary information regarding the spectrum of toxicities of the drug among this patient population.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion
Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:
Residual disease following resection of recurrent tumor is not mandated for eligibility into the study. To best assess the extent of residual disease post-operatively, a CT/ MRI should be done:
Exclusion Criteria
Responsible Party: | Teva Neuroscience ( Rivka Kreitman, Ph.D., Vice President, Innovative Research and Development ) |
Study ID Numbers: | IXR-205-21-189 |
Study First Received: | June 6, 2003 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00062504 |
Health Authority: | United States: Food and Drug Administration |
Neuroectodermal Tumors Glioblastoma Glioblastoma multiforme Astrocytoma Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Oligodendroglioma Glioma Recurrence Neoplasms, Glandular and Epithelial |
Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial |